Zemdri (Plazomicin) for Complicated UTIs: Newer IV Aminoglycoside for Resistant Infections (FDA Approved 2018)
Zevtera (Ceftobiprole) for Staph Aureus Bloodstream Infections: Novel Anti-MRSA Cephalosporin (FDA Approved 2024)
Xenleta (Lefamulin) for Community-Acquired Pneumonia: First Pleuromutilin Antibiotic (FDA Approved 2019)
Imipenem/Cilastatin/Relebactam (Recarbrio) for Carbapenem-Resistant Infections: First Triple-Combination Antibiotic (FDA Approved 2019)
